医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toyoda Gosei Invests in Friend Microbe Inc., a Startup Specializing in Wastewater Treatment Technology

2023年05月31日 AM10:00
このエントリーをはてなブックマークに追加


 

KIYOSU, Japan

Toyoda Gosei Co., Ltd. (TOKYO:7282) has invested* in Friend Microbe Inc., a startup out of Nagoya University that is growing a wastewater treatment business that uses microorganisms to reduce the waste produced in manufacturing processes.

The wastewater treatment system developed by Friend Microbe breaks down the animal and vegetable oils used in the food industry and elsewhere in a short time using microorganisms, and has proven effectiveness in cutting industrial waste oils by more than 90% and reducing offensive odors. Application of the company’s technology is also promising for the breakdown of the oil content in difficult-to-treat industrial wastewater (mineral oil, etc.) on a level similar to plant- and animal-based oils.

The minimization of waste by 2050 is one of Toyoda Gosei’s long-term environmental goals (2050 Environmental Challenge). In collaboration with Friend Microbe, the company will seek practical application of technology to break down the mineral oil from steering wheel molding processes and mold cutting processes as it pursues sustainable manufacturing with a reduced environmental impact.

Profile of Friend Microbe Inc.

Name

Friend Microbe Inc.

Location

 

Nagoya Life Science Incubator (NALIC) 104

2-22-8 Chikusa, Chikusa-Ku, Nagoya, Japan

President & CEO

Junichi Kanie

Established

June 2017

Capital

JPY125 million

* The investment was made in April 2023 through the company’s Corporate Venture Capital Dept., a dedicated internal organization for corporate venture capital investments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005004/en/

CONTACT

Toyoda Gosei Co., Ltd.

Contact: Public Relations

Chihiro Suzuki

inquiry@mlist.toyoda-gosei.co.jp

同じカテゴリーの記事 

  • KBIバイオファーマがFDA検閲を通過、世界的な大手製薬会社との商業契約を延長・拡大
  • 继成功通过FDA检查后,KBI Biopharma续签并扩大了与全球领先制药公司的商业合同
  • BCF, BREF and TBG Companies Seek Global Financial Support to Establish 1000s of Best Cure Pro Health and Medical Centers
  • Triastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech to Advance 3D Printed Oral RNA Therapeutics
  • AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China